The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Direct cardiovascular effects of glucagon like peptide-1
Open accessAbstract
Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell dysfunction as their core mechanisms of action. However, the use of traditional anti-diabetic drugs, in most cases, does not significantly reduce macrovascular morbidity and mortality. Among emerging anti-diabetic candidates, glucagon like peptide-1 (GLP-1) based therapies carry special cardiovascular implications, exerting both direct as well as indirect effects. The direct cardiovascular effects of GLP-1 and its analogs remain the focus of this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1R is expressed in the cardiovascular system, and its knockout has implications for cardiovascular function.43,44”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 1×
“The robust relationship between these two entities has been largely attributed to oxidative stress caused by hyperglycemia, although a few studies have failed to demonstrate a significant reduction in cardiovascular risk as a result of intense glycemic control [84-86].”
BackgroundInternational Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
The American Journal of Physiology
(1899) · The American Naturalist · doi:10.1086/277182 · Cited by 5,654
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“The robust relationship between these two entities has been largely attributed to oxidative stress caused by hyperglycemia, although a few studies have failed to demonstrate a significant reduction in cardiovascular risk as a result of intense glycemic control [84-86].”
BackgroundIndian Journal of Experimental Biology
(2022) · Indian Journal of Experimental Biology · doi:10.56042/ijeb · Cited by 3,392
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698 · cited 1×
“Most of these risk factors overlap with those of type 2 diabetes mellitus (T2DM) and past studies have demonstrated such a strong relationship between these two entities that AHA has declared “diabetes is a cardiovascular disease” [3].”
BackgroundRole of Endothelial Dysfunction in Atherosclerosis
Davignon, J., & Ganz, P. (2004) · Circulation · doi:10.1161/01.cir.0000131515.03336.f8 · Cited by 2,513 · cited 1×
“Since reduced anti-coagulant properties and increased pro-inflammatory mediators and reactive oxygen species play important roles in the development of both endothelial dysfunction and atherosclerosis, the association between the two is almost ubiquitous [88].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“However, removal of the first 6 amino acids yields shorter compounds (7–37 and 7–36) that have enhanced biological activity [14].”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“43,44 GLP-1R is present in the CNS, and its absence might contribute to alterations in behavior, mood, or cognitive function.”
BackgroundThe Role of the Autonomic Nervous System in the Pathophysiology of Obesity
Guarino, D., Nannipieri, M., Iervasi, G., Taddei, S., & Bruno, R. M. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00665 · Cited by 242
“Furthermore, it inhibits gastric acid secretion and gastric emptying (Imeryuz et al., 1997; Edvell and Lindstrom, 1999; Sheikh, 2013).”
BackgroundKhan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · UCL Discovery (University College London) · Cited by 71
Ishii, M., Shibata, R., Kondo, K., Kambara, T., Shimizu, Y., Tanigawa, T., Bando, Y., Nishimura, M., Ouchi, N., & Murohara, T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.557835 · Cited by 61
“A number of studies have shown that GLP-1 attenuates ischemia-induced myocardial damage and atherosclerotic lesion formation (3) and promotes angiogenesis in endothelial cells through the Akt, PKC, and Src pathways (29).”
Background
Metadata
- Authors
- Sheikh, A.
- Affiliations
- Dow University of Health Sciences (PK)
- Corresponding author
- Sheikh, Asfandyar
- ORCID
- Sheikh, Asfandyar
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2013-08-29
- Volume
- 5
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1758-5996 (ISSN-L)
- PMC
- PMC3765965
- OpenAlex
- W2120864714
- Cited by
- 45
- References
- 145
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 1 · 2017: 7 · 2016: 7 · 2015: 2 · 2014: 3
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Greater South Information System
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, cardiovascular effects, type 2 diabetes, macrovascular complications, insulin resistance, beta-cell dysfunction, antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct cardiovascular effects of glucagon like peptide-1. https://app.cochat.ai/papers/10.1186/1758-5996-5-47
- The paper
- Sheikh, A. (2013). Direct cardiovascular effects of glucagon like peptide-1. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/1758-5996-5-47
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Cardiometabolic actions of GLP-1 and GLP-1 agonists [7].](https://figures.cochat.ai/paper-figures/3bea1564cab4498ab1702b54a1e7ecc7/direct-cardiovascular-effects-of-glucagon-like-peptide-1-figure-1.jpg)
![Figure 2 Mechanism of action of GLP-1 [25].](https://figures.cochat.ai/paper-figures/678b9b59fb6944e9abe5bb65eb5b083f/direct-cardiovascular-effects-of-glucagon-like-peptide-1-figure-2.jpg)
![Figure 3 Cardiovascular effects of DPP-4 inhibitors [27].](https://figures.cochat.ai/paper-figures/f20f53ca394545809aca2dcf68a3cb60/direct-cardiovascular-effects-of-glucagon-like-peptide-1-figure-3.jpg)